Gilead Sciences on Monday agreed to purchase Kite Pharma for $11.9 million, reports Reuters. Here are four things to know about the deal. 1. Gilead will pay $180 per share for Kite Pharma in an ...
Gilead’s Kite Pharma has tied down a licensing deal for Refuge Biotechnologies’ gene expression platform in hopes of developing new blood cancer treatments and plans to take flight with a new ...
LOS ANGELES--(BUSINESS WIRE)-- Kite Pharma, Inc., a biopharmaceutical company focused on developing innovative active immunotherapies for cancer, today announced that it has raised $15 million in an ...
Kite Pharma Inc., a cancer drug developer, on Wednesday said that it had raised $20 million in a private placement of preferred stock that included its existing backers and a new investor. The ...
Gilead Sciences has agreed to acquire Kite Pharma for approximately $11.9 billion, the companies said today, in a deal that combines the chimeric antigen receptor T-cell (CAR-T) pipeline of Kite, a ...
After recalibrating its production strategy in the late 2010s to better meet the realities of the CAR-T market, Gilead Sciences’ Kite Pharma is preparing to hit the ground running with the potential ...
With the goal of becoming a powerhouse in oncology, Gilead Sciences is closely tracking the progress of its two marketed CAR-T therapies. Armed with its CAR-T unit Kite Pharma and FDA-approved ...
– Kite Cell Therapy Business Unit at Gilead Sciences K.K. Will Manage the Sales and Promotion Activities in Japan After the Marketing Authorization Transfer – SANTA MONICA, Calif. & TOKYO--(BUSINESS ...
– Daiichi Sankyo to Transfer Yescarta Marketing Authorization in Japan to Gilead Sciences K.K. – – Kite Cell Therapy Business Unit at Gilead Sciences K.K. Will Manage the Sales and Promotion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results